Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002314 · ClinicalTrials.gov registry record · Phase 2
A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002314 is a Phase 2 study that has completed, run by Hoffmann-La Roche.
The verdict
NCT00002314, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolites with its antitumor and antiviral activities and drug toxicity.
Interventions
- DRUG Ro 24-7429
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002314
The ClinicalTrials.gov registry entry for NCT00002314 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ro 24-7429 is the first listed.
NCT00002314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002314 about?
NCT00002314 is a clinical study titled "A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma". To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population. To explore relationships between exposure to Ro 24-7429 and its metabolit...
What is the current status of trial NCT00002314?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00002314?
The interventions under investigation include: Ro 24-7429 (DRUG).
Who is sponsoring clinical trial NCT00002314?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.